Dr. Aseem Malhotra

Consultant interventional cardiologist and public-health campaigner

Cardiovascular disease • statins • metabolic health • dietary guidelines

2Episodes

147 minAnalysed

1Topic

Last reviewed: Apr 6, 2026·Credential: MBChB, MRCP·First indexed: Apr 6, 2026

About the expert

Focus: Insulin resistance and lifestyle as the root drivers of heart disease

British consultant interventional cardiologist known for challenging the LDL-cholesterol hypothesis and the over-prescription of statins. Focuses on insulin resistance and chronic inflammation as the primary drivers of heart disease and advocates a low-carb Mediterranean lifestyle approach. Author of multiple BMJ papers and books on metabolic health.

Why this matters

British consultant cardiologist whose distinctive intellectual position is to frame cardiovascular disease primarily through insulin resistance and chronic inflammation rather than LDL cholesterol, and to argue that statin efficacy in primary prevention is systematically overstated by relative-risk framing. The metabolic-cardiology piece and the absolute-risk-framing critique are partly mainstream; the broader 'LDL is downstream, not upstream' framing diverges from cardiology consensus. Malhotra is a public figure whose profile is substantially built on contesting statin-prescribing convention (multiple books, media appearances, BMJ papers) — relevant context for evaluating how strongly he weights any particular signal. Has also publicly attributed cardiac events to mRNA COVID vaccines, a position mainstream cardiology bodies do not endorse. Strongest on the lifestyle case (which is mainstream consensus); the statin-specific arguments belong in shared-decision-making territory with absolute-risk numbers; the COVID-vaccine cardiac claim should be treated as fringe.

Filter by species:

Topics covered

Cholesterol & Lipid Markers (Human)

Episodes with Dr. Aseem Malhotra

Heart Disease Is the World’s #1 Killer — Dr Aseem Malhotra Explains Why

Cardiologist Aseem Malhotra places greater emphasis on insulin resistance and chronic inflammation than on LDL cholesterol when explaining cardiovascular disease, and argues that statin benefits may overstate the perceived impact when communicated primarily using relative rather than absolute risk reductions. He points to mitochondrial side effects, the type 2 diabetes signal, and the limited absolute risk reduction in primary prevention as reasons to anchor on lifestyle. Mainstream cardiology accepts the metabolic-syndrome pathway and supports absolute-risk framing, but continues to endorse LDL-lowering as a substantial cardiovascular intervention, particularly in high-risk and secondary prevention groups. Current cardiology guidelines increasingly emphasize shared decision-making, particularly when considering statins for primary prevention at intermediate cardiovascular risk. The episode also includes Malhotra's contested position linking mRNA COVID vaccines to cardiac events — a fringe view that mainstream cardiology does not endorse.

48 minHuman

Explore episode →

Is LDL cholesterol really the main cause of heart disease?

A cardiologist argues that LDL cholesterol is a weak risk factor at best, and that insulin resistance is the real driver of heart disease. He argues statin benefits are small and often overstated to patients, and makes a strong case for explaining absolute rather than relative risk. The central claim is where he departs from the evidence: large genetic studies and trials across several different LDL-lowering therapies consistently show that lowering LDL reduces cardiovascular events.

99 minHuman

Explore episode →